GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pharma Aids Ltd (DHA:PHARMAID) » Definitions » Operating Income

Pharma Aids (DHA:PHARMAID) Operating Income : BDT74.3 Mil (TTM As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Pharma Aids Operating Income?

Pharma Aids's Operating Income for the three months ended in Mar. 2025 was BDT18.4 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was BDT74.3 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Pharma Aids's Operating Income for the three months ended in Mar. 2025 was BDT18.4 Mil. Pharma Aids's Revenue for the three months ended in Mar. 2025 was BDT102.0 Mil. Therefore, Pharma Aids's Operating Margin % for the quarter that ended in Mar. 2025 was 18.03%.

Warning Sign:

Pharma Aids Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -20%.

Pharma Aids's 5-Year average Growth Rate for Operating Margin % was -20.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pharma Aids's annualized ROC % for the quarter that ended in Mar. 2025 was 12.73%. Pharma Aids's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 19.33%.


Pharma Aids Operating Income Historical Data

The historical data trend for Pharma Aids's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Aids Operating Income Chart

Pharma Aids Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 71.76 66.34 55.26 10.68 84.35

Pharma Aids Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.94 9.97 22.25 23.66 18.39

Pharma Aids Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT74.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharma Aids  (DHA:PHARMAID) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pharma Aids's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

ROC % (Q: Mar. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Mar. 2025 ))/ count )
=73.576 * ( 1 - 22.06% )/( (455.205 + 445.792)/ 2 )
=57.3451344/450.4985
=12.73 %

where

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=584.551 - 96.703 - ( 32.643 - max(0, 178.159 - 489.987+32.643))
=455.205

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=583.215 - 94.425 - ( 42.998 - max(0, 163.094 - 489.583+42.998))
=445.792

Note: The Operating Income data used here is four times the quarterly (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Pharma Aids's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Mar. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=73.576/( ( (94.564 + max(289.661, 0)) + (93.632 + max(283.472, 0)) )/ 2 )
=73.576/( ( 384.225 + 377.104 )/ 2 )
=73.576/380.6645
=19.33 %

where Working Capital is:

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(165.224 + 87.932 + 180.944) - (96.703 + 0 + 47.736)
=289.661

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(145.034 + 72.728 + 205.579) - (94.425 + 0 + 45.444)
=283.472

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Pharma Aids's Operating Margin % for the quarter that ended in Mar. 2025 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=18.394/102.035
=18.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Pharma Aids Operating Income Related Terms

Thank you for viewing the detailed overview of Pharma Aids's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Aids Business Description

Traded in Other Exchanges
N/A
Address
345 Segun Bagicha, 1st Floor, Ramna, Dhaka, BGD, 1000
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).

Pharma Aids Headlines

No Headlines